Latest news

Interim Report for Q3 2023 Published

27 October, 2023

Read the report here

Interview with CEO Andreas Bhagwani on first large-scale delivery

18 October, 2023

Nanologica’s CEO Andreas Bhagwani interviewed by Redeye analyst Filip Einarsson regarding Nanologica’s first large-scale delivery to an insulin manufacturer for evaluation in production and what this means for the company going forward. Watch the video here (in Swedish).

Nanologica Delivers Silica to Insulin Manufacturer

17 October, 2023

Nanologica delivers silica to an insulin manufacturer in Asia against an order received last year. The delivery consists of silica for evaluation in full-scale production. The delivery is made against an order that was placed last year and Nanologica will provide the silica free of charge in return for being provided with results and insights into the final evaluation. The customer, which is one of the world’s largest insulin manufacturers, finances all other costs for

CEO Andreas Bhagwani is interviewed at Redeye after the release of the interim report Q2 2023

8 July, 2023

Intervju med vd Andreas Bhagwani gällande delårsrapporten för Q2 2023.

CEO Comment Q2 2023

7 July, 2023

ONE MILESTONE PASSED – NOW WE LOOK FORWARD During the quarter, we reached an important milestone when we were finally able to approve our product in chromatography – NLAB Saga® – and after that make the first delivery to a customer who will use it in their production of insulin. The fine-tuning of the production that we implemented at the beginning of the year were successful, and on May 3 we were able to approve

Interim Report Q2 2023 Nanologica AB (publ)

7 July, 2023

FINANCIAL SUMMARY Net sales for the second quarter amounted to TSEK 672 (210) and for the half-year to TSEK 1,026 (479) The operating loss for the quarter amounted to TSEK -13,312 (-12,397) and for the half-year to TSEK -24,032 (-27,989) Loss after tax for the quarter amounted to TSEK -14,671 (-13,473) and for the half-year to TSEK -26,764 (-29,388) Earnings per share before and after dilution were SEK -0.41 (-0.48) for the quarter and SEK

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.

Categories

News archive